Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heart rate control before cardiac CT: betablockers vs ivabradine
2025-522741-21-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ivabradine, atenolol, metoprolol and chlorthalidone in coronary arteriosclerosis (2 arms), sponsored by Central Denmark Region. Primary endpoint: Time to 10% reduction in mean heart rate from baseline. Planned start Oct 2025; status: authorised.
02
Drugs
ivabradineatenololmetoprololchlorthalidone
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-522741-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522741-21-00.